

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 6106

Insiders' dealing

Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR.CO) shall make public, transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these.

Name: Susanna Waters
Reason: Related to Nicholas Waters, CEO of NeuroSearch Sweden AB
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 1 April 2008
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 1,200
Market value (DKK): 327,600

Name: Anita Milland
Reason: Vice President, CFO
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 1 April 2008
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 500
Market value (DKK): 134,250

Contact person:

Anita Milland, Vice President, CFO, telephone: +45 2016 3432

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK, ACR343 in Parkinson's disease (Phase I) and NSD-788 in anxiety a.o. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.